ArticleAdvanced healthcare materials2023
An In Vitro and Ex Vivo Analysis of the Potential of GelMA Hydrogels as a Therapeutic Platform for Preclinical Spinal Cord Injury.
Article in Advanced healthcare materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Interferon regulatory factor 4-releasing 3D-printed scaffolds enhance spinal cord repair by modulating macrophage polarization.Neural regeneration research · 2026Article
- Tea egg-inspired high mechanical strength hydrogel microneedle patch combined with tea polyphenol-magnesium nanoparticles promotes spinal cord injury repair.Materials today. Bio · 2026Article
- Redefining 3D cell culture: Human methacryloyl platelet lysates hydrogels for reliable, consistent, and ethical applications.Materials today. Bio · 2026Article
- 3D HucMSCs derived extracellular vesicles enhanced therapeutic efficacy in treating intrauterine adhesions via BECN1 delivery.Materials today. Bio · 2026Article
- Ethanol precipitation with cooling enables rapid purification of gelatin methacryloyl (GelMA) with increased yield and preserved solution-state organisation.Scientific reports · 2026Article
- Blended and Microparticle Composite Hyaluronan Hydrogels with Programmable Degradation through Selective Oxidation.ACS polymers Au · 2026Article
- Localised delivery of interleukin-13 from a PLGA microparticle embedded GelMA hydrogel improves functional and histopathological recovery in a mouse contusion spinal cord injury model.Bioactive materials · 2025Article
- Cryogel scaffolds for localised delivery of lipopolysaccharide in organotypic spinal cord slice cultures: A novelMaterials today. Bio · 2025Article
- Forced polarisation of microglia by IL-13 is modified by inflammatory and microenvironmental context.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- 3D-printed advanced scaffold armed with exosomes derived from human skeletal stem cell identified by single-cell RNA sequencing enhances osteochondral regeneration.Bioactive materials · 2025Article
- Ultrasound-driven wireless piezoelectric hydrogel synergizes with cotransplantation of NSCs-hUCMSCs for structural and functional recovery in spinal cord injury.Materials today. Bio · 2025Article
- A cryo-shocked M2 macrophages based treatment strategy promoting repair of spinal cord injury via immunomodulation and axonal regeneration effects.Journal of nanobiotechnology · 2025Article
- Local delivery of EGFRBioactive materials · 2024Article
- Exosomes derived from CD271Theranostics · 2024Article
- ThermoCyte: an inexpensive open-source temperature control system forRoyal Society open science · 2023Article
- An In Vitro and Ex Vivo Analysis of the Potential of GelMA Hydrogels as a Therapeutic Platform for Preclinical Spinal Cord Injury.Advanced healthcare materials · 2023Article
- Versatile Potential of Photo-Cross-Linkable Silk Fibroin: Roadmap from Chemical Processing Toward Regenerative Medicine and Biofabrication Applications.Biomacromolecules · 2023Review
- Recent advances in lipid nanovesicles for targeted treatment of spinal cord injury.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a devastating condition with no curative therapy currently available. Immunomodulation can be applied as a therapeutic strategy to drive alternative immune cell activation and promote a proregenerative injury microenvironment. Locally injected hydrogels carrying immunotherapeutic cargo directly to injured tissue offer an encouraging treatment approach from an immunopharmacological perspective. Gelatin methacrylate (GelMA) hydrogels are promising in this regard, however, detailed analysis on the immunogenicity of GelMA in the specific context of the SCI microenvironment is lacking. Here, the immunogenicity of GelMA hydrogels formulated with a translationally relevant photoinitiator is analyzed in vitro and ex vivo. 3% (w/v) GelMA, synthesized from gelatin type-A, is first identified as the optimal hydrogel formulation based on mechanical properties and cytocompatibility. Additionally, 3% GelMA-A does not alter the expression profile of key polarization markers in BV2 microglia or RAW264.7 macrophages after 48 h. Finally, it is shown for the first time that 3% GelMA-A can support the ex vivo culture of primary murine organotypic spinal cord slices for 14 days with no direct effect on glial fibrillary acidic protein (GFAP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.